AD-35

• Description :

  AD-35 is an orally active anti-Alzheimer's disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC50 values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu²⁺ and Fe³⁺, but its chelating ability for Zn²⁺ is relatively weak. AD-35 can inhibit Aβ aggregation and disassemble the formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function[1].

• UNSPSC :

  12352005

• Target :

  Amyloid-β; Cholinesterase (ChE) ; ERK; Interleukin Related; TNF Receptor

• Related Pathways :

  Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling; Stem Cell/Wnt

• Field of Research :

  Neurological Disease

• Smiles :

  O=C(N(CCC1CCN(CC2=CC=CC=N2)CC1)C34CC4)C(C3=C5)=CC6=C5OCO6.OP(O)(O)=O

• Molecular Formula :

  C24H30N3O7P

• Molecular Weight :

  503.48

• References & Citations :

  [1]Li L, et al. Multifunctional Compound AD-35 Improves Cognitive Impairment and Attenuates the Production of TNF-α and IL-1β in an Aβ25-35-induced Rat Model of Alzheimer's Disease. J Alzheimers Dis. 2017;56 (4) :1403-1417.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  AChE; IL-1

• CAS Number :

  [1531586-64-7]